多发性骨髓瘤与新生血管形成  

Angiogenesis in multiple myeloma

作　　者：黄昊[1] 房佰俊[1] 

机构地区：[1]郑州大学附属肿瘤医院(河南省肿瘤医院)血液科,450008

出　　处：《中华临床医师杂志（电子版）》2015年第24期145-148,共4页Chinese Journal of Clinicians(Electronic Edition)

摘　　要：尽管大剂量化疗和和造血干细胞移植提高了多发性骨髓瘤(MM)的完全缓解率,但其复发率高,是一种不可治愈的疾病。目前,研究新生血管形成尤其是血管内皮生长因子(VEGF)已经成为生物医学的焦点,由此产生的单克隆抗VEGF抗体bevazicumab等各类靶向药物,显示出显著的临床前和临床的抗肿瘤活性。已知浆细胞的累积可以诱导骨髓层面的基础血管形成,支持肿瘤细胞的生长,加速疾病的进展。这里,我们讨论肿瘤血管生成的机制,并总结现有的和潜在的抗MM血管生成剂,以寻求MM新的治疗方案。Though high-does chemotherapy and stem cell transplantation have improved the rate of complete remission of multiple myeloma (MM), MM is still an incurable disease because of the relapsed or progression. Research on the formation of angiogenesis in general and vascular endothelial growth factor (VEGF) in particular is a major focus in biomedicine and has led to the clinical approval of the monoclonal anti-VEGF antibody bevazicumab and other anti-angiogenic agents, showing significant preclinical and clinical anti-cancer activity. As reported, plasma cells accumulating can induce angiogenesis on bone marrow level, support tumor growth, accelerate disease progression. In this review we discussed the mechanisms of tumor angiogenesis, summarized the existing and potential anti-angiogenic agents, to explore new treatment options for MM.

关 键 词：多发性骨髓瘤 新生血管形成 靶向治疗药物 

分 类 号：R733.3[医药卫生—肿瘤]